ClinicalTrials.gov
public full text
Public Domain
N-Acetylcysteine for Patients With COPD and ChronicBronchitis
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive pulmonary disease (COPD), particularly for those who have accompanying symptoms of chronic cough and sputum production. Randomized, placebo controlled indicate that it is safe and that it may have some clinical benefit when used at relatively low doses. It is postulated that substantially higher doses of NAC will be well-tolerated and will provide better symptom control while also decreasing blood makers of oxidant stress and inflammation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rhodiola Crenulata as an Adjunctive Therapy in COPD#863661
- N-Acetylcysteine for Patients With COPD and Chronic Bronchitis#904329
- Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)#915047
- Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19#880151
- Inflammatory Regulation Effect of NAC on COVID-19 Treatment#826937
Record · ID 828912
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive